Introduction: IMI is a Public-Private Partnership between the EC and the European Federation of Pharmaceutical Industries and Associations (EFPIA), operational since 2007. Refer to the factsheet for a condensed overview on IMI.
Objectives: To invigorate the European biopharmaceutical sector; to provide faster access to better medicines for European citizens, through identifying primising drug candidates with greater certainty as early as possible. Thus the objective of IMI is not to develop new drugs, but to address the bottlenecks in current drug developement processes.
Target public: Each project has to include at least 2 SMEs or universities and 2 industry partners which are members of EFPIA.
Key research priorities:
- Safety sciences
- Increasing practicability of biomarkers and biobanks
- Coping with regulatory and legel hurdles
- Knowledge management
- Science communication
- Neuro-psychiatric disorders/brain diseases
- Inflammatory diseases
- Metabolic diseases including cardiovascular diseases
- Infectious diseases
- Pharmacogenetics and taxonomy of human diseases
- Rare diseases and stratified therapies
- Systems approaches in drug research
- Beyond high throughput screening - pharmacological interactions at the molecular level
- Drug compound development
- Advanced formulations
- Stem cells for drug development and toxicity screening
- Integration of imaging techniques into drug research
Calls: The 4th IMI call closed on 18 October 2011.
The 5th IMI call has been launched. The call has a budget of 80 million Euros. The submission deadline for stage 1 expression of interests is over (deadline 16th May 2012).
More information on the topics can be found at http://www.imi.europa.eu/content/stage-1-3 . Please find here the Independent Observer`s Report of the Evaluation of Stage 1 of the 5th Call for proposals
The first-ranked Applicant Consortia from IMI`s 5th Call-stage 1 have been invited to form Full Consortia with the corresponding EFPIA participants and to prepare and submit Full Project Proposals (FPPs). The deadline for submission of stage-2 is over (deadline 13th September 2012).
More information can be found at http://www.imi.europa.eu/content/stage-2-3
The 6th IMI call consists of one theme Combating Antibiotic Resitance: NewDrugs4BadBugs (ND4BB) and was launched on 23 May 2012. The deadline for stage 1 expression of interest is over (deadline 9th July 2012).
More information on the topics can be found at
IMI launched the 7th Call for proposals on 17th July 2012. The budget for this Call is 13 million Euros for 2 topics. The deadline for stage 1 submission of interest is over (9th October 2012).
Detailed information on the topics can be found at
IMI launched a new Call for proposals on 21st August 2012 to explore new scientific opportunities in ongoing IMI JU collaborative projects 2012/2013. Proposals may be submitted continuously from the date of publication of the Call until 15 December 2013.
Note: Only coordinators from ongoing IMI projects are eligible for funding
More information on this Call are available at
IMI launched the 8th Call for proposal on 17th December 2012. The deadline for stage 1 submission of interest is over (19th March 2013)
Detailed information on the 8th Call can be found at
All information about future IMI calls (9th Call for proposal under consideration) are available here http://www.imi.europa.eu/content/future-topics
Submission and evaluation follow a two-stage process: Consortium members from academia, SMEs etc submit an Expression of Interest (EoI). If evaluated favourably, they are invited to submit a full proposal together with the large industry (EFPIA) consortium members.
IMI is looking for proposal evaluators, which are drawn from the FP7 evaluators database. If you are interested in evaluating IMI EoIs and full proposals, register as expert on the dedicated Cordis website including IMI-specific keywords. The advantages are obvious: Working with EFPIA representatives enhances your network for future collaborations, and you become an expert in IMI EoI and proposal structure and the associated Dos and Don'ts.
Target public: SME, industry and research institutes NMP is particularly relevant
The latest information on IMI and its calls is included in most events covering the FP7 Health theme.
How can we help you? Discover the Euresearch Services!
Contact Point for information & advise on IMI: Dr. Sasha Hugentobler, Swiss NCP Health